I have no issue with you criticising the commercialisation...

I have no issue with you criticising the commercialisation approach we have taken at RAC, but if you post it elsewhere it is difficult to correct any misunderstandings you have about what we are doing. We are not taking the path of least resistance, we are actually taking the difficult path of bring bisantrene back to market without dilution our investors to oblivion.

Sure we could issue a few billion shares and spend $150m a year on development to selfishly advance bisantrene, but that path will result in all our investors being wiped out and ultimately damage the future of the entire biotech industry here in Australia. If we are going to have a viable future for biotech here (and have Australia companies play our part in curing diseases like cancer) we need biotechs to generate returns for investors, not just act as glorified charities or vehicles supporting the lifestyle of management.